We are live on ! Find out more
AA

ALPS Advisors Portfolio holdings

AUM $21.3B
1-Year Est. Return 21.71%
This Fund
S&P 500
This Quarter Est. Return
+39.3%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$7.46B
AUM Growth
+$995M
Cap. Flow
-$777M
Cap. Flow %
-10.41%
Top 10 Hldgs %
43.11%
Holding
851
New
66
Increased
156
Reduced
545
Closed
77

Top Buys

Rank Stock Value
1
OKE icon
Oneok
OKE
+$19.7M
2
NWL icon
Newell Brands
NWL
+$17.6M
3
NEM icon
Newmont
NEM
+$6.91M
4
COTY icon
Coty
COTY
+$5.93M
5
VIR icon
Vir Biotechnology
VIR
+$5.4M

Sector Composition

Rank Sector Weight
1 Energy 52.96%
2 Financials 9.94%
3 Healthcare 5.17%
4 Technology 4.58%
5 Consumer Discretionary 3.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CRM icon
201
Salesforce
CRM
$134B
$2.71M 0.04%
14,481
-1,782
-11% -$300K
PRNB
202
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$2.69M 0.04%
45,076
-14,532
-24% -$898K
ALEC icon
203
Alector
ALEC
$164M
$2.63M 0.04%
107,806
-32,307
-23% -$892K
QURE icon
204
uniQure
QURE
$2.68B
$2.63M 0.04%
58,307
-19,405
-25% -$1.15M
MRK icon
205
Merck
MRK
$324B
$2.62M 0.04%
35,523
+14,149
+66% +$1.07M
PLD icon
206
Prologis
PLD
$138B
$2.62M 0.04%
28,056
-1,453
-5% -$130K
ZTS icon
207
Zoetis
ZTS
$31.6B
$2.62M 0.04%
19,085
-966
-5% -$126K
SPWR
208
DELISTED
SunPower Corporation Common Stock
SPWR
$2.58M 0.03%
514,833
+53,995
+12% +$247K
IBN icon
209
ICICI Bank
IBN
$106B
$2.57M 0.03%
276,411
+54,687
+25% +$486K
DRNA
210
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.56M 0.03%
100,837
-23,574
-19% -$508K
BSX icon
211
Boston Scientific
BSX
$65.8B
$2.55M 0.03%
72,620
+24,922
+52% +$898K
EIDX
212
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$2.51M 0.03%
52,566
-15,600
-23% -$726K
AUPH icon
213
Aurinia Pharmaceuticals
AUPH
$1.97B
$2.5M 0.03%
+153,544
New +$2.46M
AMRC icon
214
Ameresco
AMRC
$1.15B
$2.49M 0.03%
89,590
+13,497
+18% +$272K
SWTX
215
DELISTED
SpringWorks Therapeutics
SWTX
$2.46M 0.03%
58,673
-19,510
-25% -$694K
MINT icon
216
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund
MINT
$17B
$2.45M 0.03%
24,110
-155
-0.6% -$15.6K
LGND icon
217
Ligand Pharmaceuticals
LGND
$6.02B
$2.45M 0.03%
35,102
-13,006
-27% -$825K
LOW icon
218
Lowe's Companies
LOW
$116B
$2.44M 0.03%
18,094
+15,048
+494% +$1.72M
LDOS icon
219
Leidos
LDOS
$14.1B
$2.44M 0.03%
26,037
+23,274
+842% +$2.29M
FSK icon
220
FS KKR Capital
FSK
$2.98B
$2.42M 0.03%
172,625
-91,000
-35% -$1.28M
MDGL icon
221
Madrigal Pharmaceuticals
MDGL
$12.6B
$2.38M 0.03%
21,047
-7,006
-25% -$689K
CG icon
222
Carlyle Group
CG
$16.3B
$2.37M 0.03%
84,800
-20,900
-20% -$537K
CDNS icon
223
Cadence Design Systems
CDNS
$90B
$2.35M 0.03%
24,453
+3,268
+15% +$274K
YMAB
224
DELISTED
Y-mAbs Therapeutics
YMAB
$2.34M 0.03%
+54,239
New +$2.05M
META icon
225
Meta Platforms (Facebook)
META
$1.51T
$2.33M 0.03%
10,278
+841
+9% +$176K

Similar funds

ALPS Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, ALPS Advisors held 851 positions worth $7.46B, up 15% from $6.46B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

ALPS Advisors withdrew a net $777M in Q2 2020, closing 77 positions and reducing 545 holdings. Its most notable exit was EQM Midstream Partners, LP, an estimated $127M position sold in full.

By sector, the portfolio is most concentrated in Energy at 53% of assets, up from 51% a quarter earlier, followed by Financials and Healthcare.

Against the trend, ALPS Advisors opened a new position in Newell Brands worth $20.3M.

  • ALPS Advisors's largest Q2 2020 buy was Newell Brands: 1,279,812 shares worth $20.3M.
  • ALPS Advisors added most to Oneok in Q2 2020, an estimated $19.7M increase.
  • ALPS Advisors's biggest Q2 2020 reduction was MPLX, cutting an estimated $139M.
  • ALPS Advisors fully exited EQM Midstream Partners, LP in Q2 2020, selling an estimated $127M.
  • ALPS Advisors's ten largest holdings make up 43% of its $7.46B portfolio in Q2 2020.
  • ALPS Advisors opened 66 new positions and closed 77 in Q2 2020.
  • ALPS Advisors's portfolio value rose 15% quarter-over-quarter to $7.46B.

Based on ALPS Advisors's 13F filing for Q2 2020, filed 5 Aug 2020.